Literature DB >> 15276091

Brachial artery reactivity in asymptomatic patients with type 2 diabetes mellitus and microalbuminuria (from the Detection of Ischemia in Asymptomatic Diabetics-brachial artery reactivity study).

Georgios I Papaioannou1, Richard L Seip, Neil J Grey, Deborah Katten, Amy Taylor, Silvio E Inzucchi, Lawrence H Young, Deborah A Chyun, Janice A Davey, Frans J Th Wackers, Ami E Iskandrian, Robert E Ratner, Evelyn C Robinson, Stella Carolan, Samuel Engel, Gary V Heller.   

Abstract

Microalbuminuria is a novel atherosclerotic risk factor in patients with type 2 diabetes mellitus (DM) and predicts future cardiovascular events. Endothelial dysfunction and systemic inflammation have been proposed as common links between microalbuminuria and cardiovascular disease. However, no study has assessed the relation between microalbuminuria and vascular dysfunction as measured by brachial artery reactivity (BAR) in DM. We evaluated 143 patients (85 men; mean age 60.0 +/- 6.7 years) with DM (mean duration 8.2 +/- 7.4 years) enrolled in the Detection of Ischemia in Asymptomatic Diabetics study. Subjects were categorized as those with microalbuminuria (ratio of urinary albumin to creatinine 30 to 299 microg/mg creatinine, n = 28) and those with normoalbuminuria (ratio of urinary albumin to creatinine 0 to 29.9 microg/mg creatinine, n = 115). High-resolution ultrasound BAR testing was used to measure endothelium-dependent and endothelium-independent vasodilations. C-reactive protein was measured as a marker of systemic inflammation. Patients with microalbuminuria and normoalbuminuria had similar baseline characteristics, with the exception that those with microalbuminuria had a longer duration of DM (p = 0.03). Endothelium-dependent vasodilation at 1 minute (p = 0.01) and endothelium-independent vasodilation at 3 minutes (p = 0.007) were significantly less in patients with microalbuminuria. In addition, 96% of patients with microalbuminuria and 76% of those with normoalbuminuria had impaired endothelium-dependent vasodilation (<8%, p = 0.01). Microalbuminuria was an independent predictor of endothelium-dependent vasodilation in the entire cohort (p = 0.045) and after excluding patients on hormone replacement therapy (p = 0.01). Levels of C-reactive protein were significantly higher in patients with microalbuminuria than in those with normoalbuminuria (p = 0.02). We conclude that in DM the presence of microalbuminuria is associated with impaired endothelium-dependent and endothelium-independent vasodilations of the brachial artery and a higher degree of systemic inflammation. In addition, microalbuminuria is an independent predictor of endothelial dysfunction in asymptomatic patients with DM, especially in the absence of hormone replacement therapy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15276091     DOI: 10.1016/j.amjcard.2004.04.022

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  20 in total

1.  Value of peripheral vascular endothelial function in the detection of relative myocardial ischemia in asymptomatic type 2 diabetic patients who underwent myocardial perfusion imaging.

Authors:  Georgios I Papaioannou; Christos Kasapis; Richard L Seip; Neil J Grey; Deborah Katten; Frans J Th Wackers; Silvio E Inzucchi; Samuel Engel; Amy Taylor; Lawrence H Young; Deborah A Chyun; Janice A Davey; Ami E Iskandrian; Robert E Ratner; Evelyn C Robinson; Stella Carolan; Gary V Heller
Journal:  J Nucl Cardiol       Date:  2006 May-Jun       Impact factor: 5.952

Review 2.  Cardiovascular risk assessment in type 2 diabetes mellitus.

Authors:  Ebaa Al-Ozairi; R Jan-Willem Middelbeek; Edward S Horton
Journal:  Curr Diab Rep       Date:  2006-11       Impact factor: 4.810

Review 3.  Mechanisms, significance and treatment of vascular dysfunction in type 2 diabetes mellitus: focus on lipid-regulating therapy.

Authors:  Richard J Woodman; Gerard T Chew; Gerald F Watts
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 4.  Endothelial dysfunction over the course of coronary artery disease.

Authors:  Enrique Gutiérrez; Andreas J Flammer; Lilach O Lerman; Jaime Elízaga; Amir Lerman; Francisco Fernández-Avilés
Journal:  Eur Heart J       Date:  2013-09-07       Impact factor: 29.983

Review 5.  Endothelial dysfunction as a potential contributor in diabetic nephropathy.

Authors:  Takahiko Nakagawa; Katsuyuki Tanabe; Byron P Croker; Richard J Johnson; Maria B Grant; Tomoki Kosugi; Qiuhong Li
Journal:  Nat Rev Nephrol       Date:  2010-11-02       Impact factor: 28.314

6.  Capillary Rarefaction Associates with Albuminuria: The Maastricht Study.

Authors:  Remy J H Martens; Ronald M A Henry; Alfons J H M Houben; Carla J H van der Kallen; Abraham A Kroon; Casper G Schalkwijk; Miranda T Schram; Simone J S Sep; Nicolaas C Schaper; Pieter C Dagnelie; Dennis M J Muris; Ed H B M Gronenschild; Frank M van der Sande; Karel M L Leunissen; Jeroen P Kooman; Coen D A Stehouwer
Journal:  J Am Soc Nephrol       Date:  2016-05-09       Impact factor: 10.121

7.  Microalbuminuria is associated with impaired arterial and venous endothelium-dependent vasodilation in patients with Type 2 diabetes.

Authors:  A M V Silva; B D Schaan; L U Signori; R D M Plentz; H Moreno; M C Bertoluci; M C Irigoyen
Journal:  J Endocrinol Invest       Date:  2010-03-30       Impact factor: 4.256

Review 8.  Endothelial dysfunction in diabetes: pathogenesis, significance, and treatment.

Authors:  Sandra J Hamilton; Gerald F Watts
Journal:  Rev Diabet Stud       Date:  2013-08-10

Review 9.  Therapeutic angiogenesis in diabetes and hypercholesterolemia: influence of oxidative stress.

Authors:  Munir Boodhwani; Frank W Sellke
Journal:  Antioxid Redox Signal       Date:  2009-08       Impact factor: 8.401

10.  The markers of inflammation and endothelial dysfunction in correlation with glycated haemoglobin are present in type 2 diabetes mellitus patients but not in their relatives.

Authors:  José Manuel Gómez; Ramon Vila; Pablo Catalina; Juan Soler; Lina Badimón; Manel Sahún
Journal:  Glycoconj J       Date:  2008-03-18       Impact factor: 2.916

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.